Table 1.
Reported Median Overall Survival and Median Progression Free Survival in HCC Immunotherapy Trials
| Reference | Study Arm | Median OS/ Median PFS (Months) | Comparison Arm | Median OS/ Median PFS (Months) | Statically Significant |
|---|---|---|---|---|---|
| Finn et al, 2020 (IMBrave)39 | Atezolizumab + Bevacizumab | NR/ 6.8 | Sorafenib | 13.2/ 4.3 | Yes |
| Cheng et al, 202240 | Atezolizumab + Bevacizumab | 19.2/ 6.9 | Sorafenib | 13.4/ 4.3 | Yes |
| Qin et al, 202241 | Camrelizumab +Rivoceranib | 22.1/ 5.6 | Sorafenib | 15.2/ 3.7 | Yes |
| Finn et al, 202242 | Lenvatinib + Pembrolizumab | 21.2/ 8.2 | Lenvatinib | 19/ 8.1 | No |
| Abou-Alfa et al, 2022 (HIMALAYA)30 | Tremelimumab + Durvalumab | 16.4 | Sorafenib | 13.8 | Yes |
Abbreviations: OS, overall survival; PFS, progression free survival; NR, not reached.